TRENTON, N.J. AP – Merck & Co. has settled a lawsuit over claims the drugmaker delayed releasing disappointing results of a study management had hoped would instead boost sales of a key drug.

The settlement ends a four-year-long case shareholders had filed after the company for 21 months delayed releasing results on a study of Vytorin likely to hurt future sales of the blockbuster pill for treating high cholesterol.